Discover why BTK inhibitors have attracted interest for treating multiple sclerosis, as a few late-stage candidates close in ...

Sanofi is handing back a phase 2-stage natural killer (NK) cell engager and canceling another cancer trial as the Big Pharma ...

European drugmakers are urging the EU to allow higher medicine prices, warning that without stronger investment incentives, ...

"European price controls and austerity measures reduce the attractiveness of its markets," Novartis CEO Vas Narasimhan and ...

Older adults with cancer respond just as well as younger patients to immune checkpoint inhibitors despite age-related immune system differences, according to a new study.